Chemical Management

TECHNOLOGIES TO WATCH IN 2022

April 5, 2022

TECHNOLOGIES
Each year, MGSSI’s Technology Foresight Center identifies technologies that deserve particular attention, and
provides a forward-looking overview of those technologies and insights.

Spotlight

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, anabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Anabasum has demonstrated positive clinical data in Phase 2 studies evaluating anabasum for the treatment of diffuse cutaneous systemic sclerosis and for the treatment of cystic fibrosis. Additionally, anabasum is being evaluated in a Phase 2, 12-month open-label extension study in systemic sclerosis, a Phase 2 study in skin-predominant dermatomyositis with a 12-month open-label extension, and another Phase 2 study in systemic lupus erythematosus is scheduled to commence in H2 2017.

OTHER WHITEPAPERS
news image

Characterizing Molecular Structure in Synthetic and Natural Polymers by Multi-Angle Light Scattering

whitePaper | September 9, 2022

This note provides a brief overview of basic principles of the detection and characterization of branching by means of multi-angle light scattering (MALS) detector.

Read More
news image

Optimising chemistry performance through heterogeneous catalyst design

whitePaper | December 5, 2022

Chemical catalysis by platinum group metal (PGM) based materials is an essential synthetic technology for the fine chemical industry. Catalysis enables the acceleration of the reaction rate using a substance that itself is not consumed.

Read More
news image

Planet Positive Chemicals

whitePaper | September 24, 2022

Climate action in the global chemical industry is lagging compared to other sectors. As of August 2022, only seventeen industry players had committed to targets in line with a 1.5 degrees future as part of the Science Based Targets initiative (SBTi).

Read More
news image

Lithium batteries whitepaper

whitePaper | December 25, 2022

Founded in 1903, Brookes Bell is a leading multi-disciplinary technical and scientific consultancy serving the marine and energy sectors. We investigate, troubleshoot and advise on a broad range of marine and energy matters and enjoy a reputation.

Read More
news image

Advanced Recycling: Seizing the Circular Plastics Opportunity

whitePaper | March 11, 2022

Our modern way of life would not be possible without plastics. However, better post-use management of plastic products is required, and we need to move to a circular economy for plastics that recognizes plastics as a resource or feedstock, not a waste.

Read More
news image

PLASTIC FOR PROFIT

whitePaper | July 12, 2021

The author wishes to thank Willie Wilson for his advice and support with stakeholder mapping throughout the project, Linh Tran Phuong Dang for helping with research and data collection, and many individuals and organizations that have shared their knowledge, including INTERPOL’s Pollution Crime Working Group; the environmental agencies of the United Kingdom, Zambia, Ghana and South Africa; the Environment and Natural Resources Division at the United States Department of Justice;

Read More

Spotlight

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, anabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Anabasum has demonstrated positive clinical data in Phase 2 studies evaluating anabasum for the treatment of diffuse cutaneous systemic sclerosis and for the treatment of cystic fibrosis. Additionally, anabasum is being evaluated in a Phase 2, 12-month open-label extension study in systemic sclerosis, a Phase 2 study in skin-predominant dermatomyositis with a 12-month open-label extension, and another Phase 2 study in systemic lupus erythematosus is scheduled to commence in H2 2017.

Events